title: Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
abstract: It is now well recognized that treatment with anti-IgE antibodies like omalizumab is a valuable option in patients with allergic asthma who remain symptomatic despite optimal treatment. To our knowledge, treatment with omalizumab in patients with nonallergic asthma has not been reported. We present and discuss a patient with severe asthma and elevated total IgE who had a negative radioallergosorbent (RAST) test result and a negative skin-prick test result; the patient showed a dramatic improvement with this treatment strategy.
authors.affiliation: Department of Pulmonology, University Medical Center Groningen, Groningen, the Netherlands. m.van.den.berge@int.umcg.nl
authors.forename: Maarten
authors.initials: M
authors.lastname: van den Berge
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Pauw
authors.forename: Jan G R
authors.initials: JG
authors.lastname: de Monchy
authors.forename: Cees A
authors.initials: CA
authors.lastname: van Minnen
authors.forename: Dirkje S
authors.initials: DS
authors.lastname: Postma
authors.forename: Huib A M
authors.initials: HA
authors.lastname: Kerstjens
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D001999:Bronchoscopy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D007279:Injections, Subcutaneous; D008875:Middle Aged; D000069444:Omalizumab; D010328:Patch Tests; D013902:Radiography, Thoracic; D012720:Severity of Illness Index
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E